Saudi Journal of Gastroenterology

NEW HORIZON
Year
: 2008  |  Volume : 14  |  Issue : 1  |  Page : 40--42

Sorafenib in the treatment of advanced hepatocellular carcinoma


Ali Ben Mousa 
 Division of Gastroenterology and Hepatology, Department of Medicine, Riyadh Military Hospital, Riyadh, Saudi Arabia

Correspondence Address:
Ali Ben Mousa
Division of Gastroenterology and Hepatology, Department of Medicine, Riyadh Military Hospital, P.O. Box 7897, Riyadh 11159
Saudi Arabia

Management of advanced hepatocellular carcinoma (HCC) is still a challenge to physicians since these patients are not candidates for surgical or ablative therapy. The disease carries a very poor prognosis with an expected survival of 4-6 months. No chemotherapeutic agent has been proven to improve the clinical outcome in such patients. A multikinase inhibitor, sorafenib, previously tested and found effective in other solid tumors recently found to significantly improve survival in patients with advanced HCC. Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis. It was well tolerated at a dose of 400 mg twice daily and permanent discontinuation of the drug was rarely required.


How to cite this article:
Mousa AB. Sorafenib in the treatment of advanced hepatocellular carcinoma.Saudi J Gastroenterol 2008;14:40-42


How to cite this URL:
Mousa AB. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol [serial online] 2008 [cited 2022 Jan 23 ];14:40-42
Available from: https://www.saudijgastro.com/article.asp?issn=1319-3767;year=2008;volume=14;issue=1;spage=40;epage=42;aulast=Mousa;type=0